New to the Big Apple tech scene, Cleerly launched out of stealth mode and is working to shed light on causes and treatments of heart disease and heart attacks. The company announced on Monday its $43 million Series B funding round led by Vensana Capital as it aims to create a new standard of care for patients looking to keep their heart healthy.
About 655,000 Americans die from heart disease each year in the U.S., according to data from the Centers for Disease Control and Prevention (CDC). As this accounts for every one in four deaths, heart disease is ranked as the leading cause of death for men and women across the country.
Cleerly was created to address this statistic and provide more visibility and understanding around heart disease. Using AI and machine learning technology, the company’s digital care pathway solution translates advanced coronary imaging to help identify those at risk of heart attacks. It aims to provide physicians, clinicians, patients and payers alike with tools to help navigate cardiovascular care.
For clinicians, Cleerly enables them to grasp the importance of data without needing to understand the advanced imaging it was gathered from. On the patient’s end, the platform provides personalized tools to further their knowledge about their health, as well as tools to help them track changes in their condition over time.
“Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death. We use 3D mammograms, colonoscopies and lung CT scans to find and prevent breast, colon and lung cancer, but we haven’t had similar capabilities for the world’s number-one killer — heart disease,” Dr. James Min, founder and CEO of Cleerly, said in a statement. “Through the application of artificial intelligence that is constantly being refined with our unprecedented volume of accruing and exclusive clinical data, Cleerly is finally bringing heart disease diagnosis and prevention into the 21st century.”
With its Series B funding, the company is aiming to expand the commercial reach of its platform, expand its operational capabilities and strategic partnerships as well as invest in R&D. Additional participants in this round include LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures and others. To date, Cleerly has raised $54 million in funding.
